115 responded to recruitment advertisement

1st and 2nd phase
Screening for eligibility

35 excluded
21 met exclusion criteria
14 had higher CVs in SIgA

80 eligible subjects

Exclusion
week 0 (n = 10) took forbidden drug (N = 3), changed affecting drug (N = 1), or poor compliance (N = 1)
week 2 (n = 10) took forbidden drug (N = 1), or affecting drug (N = 1)
week 4 (n = 14) took forbidden drug (N = 1), or affecting drug (N = 1)
week 6 (n = 14) took forbidden drug (N = 1)
week 8 (n = 14) week 10 (n = 16) took forbidden drug (N = 1)
week 12 (n = 20) took forbidden drug (N = 1), or affecting drug (N = 1)

Placebo group
(N = 40)

Saliva collection
week 0 (n = 79)
no saliva (n = 1)
week 2 (n = 78)
absence (N = 1)
week 4 (n = 80)
week 6 (n = 78)
absence (N = 1)
week 8 (n = 74)
absence (N = 3)
week 10 (n = 76)
absence (N = 2)
week 12 (n = 80)

Analysis
week 0 (n = 70)
week 2 (n = 68)
week 4 (n = 66)
week 6 (n = 64)
week 8 (n = 62)
week 10 (n = 60)
week 12 (n = 60)

b240 group
(N = 40)

Saliva collection
week 0 (n = 80)
week 2 (n = 79)
handling mistake (n = 1)
week 4 (n = 80)
week 6 (n = 80)
week 8 (n = 72)
absence (N = 4)
week 10 (n = 80)
week 12 (n = 80)

Analysis
week 0 (n = 76)
week 2 (n = 75)
week 4 (n = 70)
week 6 (n = 72)
week 8 (n = 62)
week 10 (n = 70)
week 12 (n = 66)

Exclusion
week 0 (n = 4) took forbidden drug (N = 1), or changed affecting drug (N = 1)
week 2 (n = 4)
took affecting drug (N = 1)
week 4 (n = 10) took forbidden drug (N = 3), or affecting drug (N = 1)
week 6 (n = 8)
week 8 (n = 10) took affecting drug (N = 1)
week 10 (n = 10) took forbidden drug (N = 1)
week 12 (n = 14) poor compliance (N = 1), or took affecting drug (N = 1)